openPR Logo
Press release

Global HCV Market to 2024

11-15-2017 03:54 AM CET | Health & Medicine

Press release from: Optima insights Pvt Ltd

/ PR Agency: optima insights
HCV Market

HCV Market

HCV market was valued at $12.5bn in 2015 and is forecast to contract 4.1% CAGR between 2015 and 2024, reaching 2024 global sales of $8.2bn. The volume of HCV patients who will be treated over the next several years is expected to decline resulting in market contraction.

The World Health Organization (WHO) estimates that 185 million people globally are infected with Hepatitis C virus (HCV), with 3 to 4 million new infections each year. Roughly 75% of these cases fail to resolve acutely and evolve into a chronic state. Most estimates peg the number of patients with chronic hepatitis C infections at 3 million in the U.S. (1.0-1.8% of the population), although some recent estimates suggest that there could be as many as 8 milllion people (2.5% of the population). A slightly greater number of cases exists in Europe (7-12 million), with a large infected population in Asia (70 million+).
Global HCV Patients Treated, 2015 - 2024 (in 1000’s)

Request For TOC :

“Current Treatment algorithm”

Protease inhibitors were the first direct antiviral drugs on the market for HCV. Vertex/J&J’s Incivek (telaprevir) and Merck’s Victrelis (boceprevir) were launched during 2011 and rapidly became part of the standard of care regimens.

The approval of Gilead’s Sovaldi (sofosbuvir) in December 2013 was a watershed moment as it marked the availability of the first interferon-free regimens. The approval of Gilead’s Harvoni (sofosbuvir and ledispavir) in October 2014 brought the first FDA-approved interferon free regimen for genotype 1 HCV patients, the largest HCV population in the U.S.

The approval of Gilead’s Epclusa (sofosbuvir/velpatasvir) in June 2016 further improved the standard of care in GT 2 and 3 patients. Overall Gilead’s sofosbuvir based regimens appear to have a best-in-class profile, with the highest cure rates, shortest duration of therapy, fewest pills, and best safety/tolerability profile.

J&J’s Olysio became the protease inhibitor of choice following its November 2013 FDA approval and launch, posting 2014 worldwide sales of $2.3bn as it was widely used in combination with Sovaldi (sofosbuvir) in an interferon-free regimen for GT 1 patients.

“The Era of interferon-free regimens has arrived”

Following the approval of Gilead’s Harvoni in October 2014, AbbVie’s Viekira Pak in December 2014, and Merck’s Zepatier in January 2016, three FDA approved IFN–free regimens are available for genotype 1 patients. These interferon-free regimens have revolutionized treatment, as they have high 95%+ cure rates, good safety and tolerability, with short (8-12 week) treatment times.

“Innovations in HCV Treatment”

There are 5 key discovery programs that could disrupt the HCV landscape in the foreseeable future. These include 1) Gilead's triplet at EASL, 2) Merck's nuke study, 3) Achillion's doublet nuke regimen, 4) Regulus' novel microRNA approach that could be used with pills, and 5) Abbvie/Enanta's next generation protease regimen.

Merck’s Zepatier (elbasvir and grazoprevir) was approved by the FDA for the treatment of adult patients with HCV genotypes 1 and 4 in January 2016. Zepatier also produced strong Phase III data, with 95% SVR rates in most genotype 1 and 4 patient groups.

There are a number of other HCV candidates in development, including new regimens from Gilead, Abbvie, and Merck. J&J is also trying to develop an interferon free regimen.

“Gilead, Merck, Abbvie, GSK, Roche, Bristol Myers & J&J are some of the key players in HCV market"

Gilead and Bristol Myers led the HCV market with meaningful market share in 2015. We expect total sales to decline through 2024, though we anticipate Gilead will maintain majority share. We anticipate that Merck and AbbVie will gain share through the launch of their next-generation interferon-free regimens.
Merck and Roche lead the market for pegylated alpha-IFNs. We predict that the interferon market will continue to contract as the launch of direct antiviral combination regimens has the potential to eliminate the need for interferon. J&J and Bristol Myers could see their franchises sales to decline through 2024.

“Reimbursement insights”
Our Services :

HCV regimens are heavily discounted & rebated. Abbvie’s Viekira and Merck’s Zepatier have brought new competition to HCV, putting payors in a strong negotiating position leading to price declines. Moreover, contracts with payors that offer price discounts for the removal of restrictions on which HCV patients can be treated have pressured the average revenue per HCV patient. Gilead reports that the standard 12 week Epclusa regimen will be priced at of $75K. Epclusa is priced for $84K per 12 week regimen and Harvoni at $94K per 12 week regimen.

Optima Insights is an innovative research and insights driven enterprise committed to offer actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content holds the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them take better business decisions towards attaining market leadership.

Chakradhar G
Manager International Marketing
1 MMC, Road, Chennai. Pin - 600060,
Tamil Nadu, I N D I A

Phone: +91 966 6620 365
Whatsapp: +91 966 6620 365

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global HCV Market to 2024 here

News-ID: 816744 • Views:

More Releases from Optima insights Pvt Ltd

Endometriosis Treatment Market is Expected to Reach $3.43 bn by 2027
The Endometriosis Treatment Market was valued at US $2.64 billion in the year 2019 and is estimated to reach US $3.43 billion by 2027, at a CAGR of 3.36%. The growth of tissue outside the uterus similar to lining of uterus (endometrium) refers to Endometriosis. Areas of endometrial tissue growth often occur in ovaries, fallopian tubes, peritoneum and outer surfaces of bladder, uterus, intestines, and rectum and rarely spread beyond pelvic
Inflammatory Bowel Disease (IBD) Treatment Market is Expected to Reach $15.5 bn …
The Inflammatory Bowel Disease (IBD) treatment market share was US$ 11.38 Bn in the year 2018. The market is anticipated to grow at a rate of 3.94%, through the forecast period to reach US$ 15.5 Bn by the year 2027. Inflammatory Bowel Disease (IBD) usually denotes disorders characterized by the inflammation in the digestive system. Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome are two different disorders that are often confused
Polycystic Ovarian Syndrome (PCOS) Treatment Market is Expected to Reach $5.59 b …
The Polycystic Ovarian Syndrome (PCOS) Treatment Market was valued at US $3.74 billion in the year 2019 and is estimated to reach US $5.59 billion by 2027, at a CAGR of 5.18%. Polycystic Ovarian Syndrome (PCOS), also referred to as Stein-Leventhal syndrome is a hormonal disorder characterized by enlarged ovaries and formation of numerous small cysts (fluid-filled sacs) on the outer edges of the ovaries. Symptoms of PCOS include irregular periods,
Veterinary Vaccines Market is Expected to Reach $13.51 bn by 2027
The Veterinary Vaccines Market was valued at US $7.91 billion in the year 2018 and is estimated to reach US $13.51 billion by 2027, at a CAGR of 6.13%. Generally, vaccines are effective in preventing infectious diseases. Veterinary vaccines especially reduce the burden of the disease in animals and also helps in preventing several zoonotic diseases also. There are four types of veterinary vaccines available depending on preparation type, they are

All 5 Releases

More Releases for HCV

HCV Vehicles To Drive Automotive Turbocharger Hose Market Forecast Worldwide
An increase in manufacturing and sales of commercial vehicles will significantly influence the automotive turbocharger hose industry trends through the next few years. There is a strong demand for fuel-efficient passenger vehicles in countries like U.S., China, Germany, the UK, and France. Various OEM participants are consistently working towards incorporating fuel-efficient engines to enhance the performance of the vehicles. Besides, there is an ease of access and abundant availability of turbocharger
Global Hepatitis C Virus (HCV) Testing Market Analysis by 2020-2025
Scope of the Report: The global Hepatitis C Virus (HCV) Testing market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. Market segmentation Hepatitis C Virus (HCV) Testing market is split by Type and by Application. For the
Human Anti HCV ELISA Kit Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Human Anti HCV ELISA Kit Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Human Anti HCV ELISA Kit players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Human
Global Hepatitis C Virus (HCV) Market Report: 2016 Edition
Hepatitis C Virus (HCV) is an infection which affects the liver which may lead to serious consequences if not taken care of. It spreads through infected blood transfusions and poorly sterilized medical equipments. The number of patients has increased significantly because its symptoms take time to be recognized before the patient progresses towards a clinically visible liver damage which worsens the situation since it may lead to liver damage or
Future of Global Hepatitis C Virus (HCV) Antiviral Market: 2020
Inflammation of liver causes hepatitis. Hepatitis C is a contagious liver disease caused due to hepatitis C virus. Hepatitis C damages and infects the liver. Hepatitis C is spread as the infected blood comes in contact with non-infected blood. Ranging in severity hepatitis C can cause acute and chronic hepatitis infection. Chronic hepatitis C is diagnosed by liver biopsy and blood tests. According to World Health Organization (WHO), globally 130
RNCOS Releases a New Report - India MCV and HCV Market Outlook
RNCOS has recently added a new Market Research Report titled, “India MCV and HCV Market Outlook” to its report gallery. India opened its doors for multinational automobile companies 20 years ago. Since then, several firms have established their production units in the country, offering a wide range of vehicles to the vast population. According to our latest report, the Indian commercial vehicle market has grown by leaps and bounds due